OMass Therapeutics Pivots From Services To Drug Discovery With Novel Mass Spect Technology

Published

November 12, 2018

OMass Therapeutics Pivots From Services To Drug Discovery With Novel Mass Spect Technology

A new UK biotech, OMass Therapeutics, has been spun out of the chemistry department at the University of Oxford to exploit expertise in “native” mass spectrometry, a technology investors believe has potential in helping to build a portfolio of novel drugs…

MORERelated News
Biotech Review of the Year
The main challenge in 2023 was that global economic conditions (war in Ukraine, war in the Middle East, increasing interest...
The Life Sciences Sector Successfully Toughs Out Economic Challenges
Miguel Silva, Strategy Director at OMass Therapeutics which spun out of the University of Oxford. The company uses novel biochemistry...
Scrip Asks…What Does 2024 Hold For Biopharma? Part 1: Business Strategy And Leadership
Ros Deegan, CEO at OMass Therapeutics, Ltd, which develops new treatments using novel mass spectrometry approaches, also urged boldness (as well...